{
    "clinical_study": {
        "@rank": "35287", 
        "acronym": "PMS", 
        "arm_group": [
            {
                "arm_group_label": "Yasmin", 
                "arm_group_type": "Active Comparator", 
                "description": "Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg)  will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months."
            }, 
            {
                "arm_group_label": "Calver", 
                "arm_group_type": "Active Comparator", 
                "description": "Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be given to the patients daily for 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Premenstrual syndrome represents a group of problems affecting most of women in reproductive\n      age. These problems include emotional and physical symptoms. In this study the efficacy of\n      oral contraceptive pills and calcium supplements in relieving these symptoms will be\n      assessed ."
        }, 
        "brief_title": "Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Premenstrual Syndrome", 
        "condition_browse": {
            "mesh_term": "Premenstrual Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Premenstrual syndrome (PMS) is de\ufb01ned as the recurrence of psychological and physical\n      symptoms in the luteal phase, which remit in the follicular phase of the menstrual cycle\n      [1].PMS will be prospectively diagnosed using the Royal college of Obstetricians and\n      Gynecologists (RCOG) recommended daily record of severity of problems (DRSP) . Women will be\n      asked to fill the diary for 2 months, only women with 30% increase in the DRSP score in the\n      week before menses in both months will be diagnosed as having PMS.\n\n      Women with PMS will be invited to participate in the study.The invitation will include a\n      clear full explanation of the study and patients will provide written consents. All patients\n      consenting to participate will be included in the trial.\n\n      Yasmin, Calver and Placebo will be enclosed in similar jars which will be numbered using a\n      computer generated random table. Women will be asked to choose a sealed envelope, each\n      envelope will contain the number allocated to the jar and special instructions on how to use\n      the medication. Yasmin will be taken once daily for 21 days starting from the 2nd day of\n      menstruation, Calver and placebo will be taken continuously. Neither the patients nor the\n      physician will be aware of the drug used. Patients will be categorized in 3 groups: group1\n      who will receive Yasmin cyclically for 3 months (Yasmin, schering, cairo, Egypt), group 2\n      who will receive Calver continuously for 3 months (Calver, Marcryl/Vertex, Cairo Egypt),\n      group 3 who will receive placebo continuously for 3 months and will act as a control group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed by prospective dairy to have PMS\n\n          -  Consenting to be included in the study\n\n          -  Age 18-40 years\n\n        Exclusion Criteria:\n\n          -  Medical disorders as hypertension or diabetes."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089620", 
            "org_study_id": "Beni-Suef 1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Yasmin", 
                "description": "will be used every 21 days for three months by the patient", 
                "intervention_name": "Yasmin", 
                "intervention_type": "Drug", 
                "other_name": "OCP"
            }, 
            {
                "arm_group_label": "Calver", 
                "description": "Calver will be given daily for 3 months", 
                "intervention_name": "Calver", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Calcium supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients will receive a placebo daily for 3 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Contraceptive Agents", 
                "Contraceptives, Oral", 
                "Contraceptives, Oral, Combined", 
                "Drospirenone and ethinyl estradiol combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Premenstrual syndrome", 
            "Oral contraceptive pills", 
            "Calcium Supplements"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beni-Suef", 
                    "country": "Egypt"
                }, 
                "name": "Beni-Suef University"
            }, 
            "investigator": [
                {
                    "last_name": "Nesreen A Shehata, Lecturer", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Abdelgany M Hassan, Lecturer", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison Between Oral Contraceptive Pills Containing Disperinone and Calcium Supplements in Therapeutic Management of Premenstrual Syndrome", 
        "overall_contact": {
            "email": "nesoomar@yahoo.com", 
            "last_name": "Nesreen A Shehata, Lecturer", 
            "phone": "00201227866337"
        }, 
        "overall_official": [
            {
                "affiliation": "Beni-Suef University", 
                "last_name": "Nesreen A Shehata, Lecturer", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cairo University", 
                "last_name": "Abdelgany M Hassan, Lecturer", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improvement of symptoms will be assessed by comparing the pre-treatment recorded DRSP with that recorded 3 months after starting treatment.", 
            "measure": "Improvement of premenstrual symptoms.", 
            "safety_issue": "No", 
            "time_frame": "3 months after starting treatment."
        }, 
        "reference": [
            {
                "PMID": "16172836", 
                "citation": "Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006 Jan;9(1):41-9. Epub 2005 Sep 20."
            }, 
            {
                "PMID": "11588078", 
                "citation": "Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001 Oct 6;323(7316):776-80."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089620"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beni-Suef University", 
            "investigator_full_name": "Nesreen Abdel Fattah Abdullah Shehata", 
            "investigator_title": "Nesreen Abdel Fattah Abdullah Shehata, Beni-Suef University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Beni-Suef University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beni-Suef University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}